


[EBMT](#)

[Annual report](#)

[2023](#)



[Science Education Patient Care & Advocacy](#)

[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2023](#) [Organisational Structure 2023](#) [Financial Highlights 2023](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Zinaida Perić

TCWP Chair

Croatia

Major achievements

During 2023 the TCWP finalised several important projects including the **new guidelines** on prevention and management of GVHD as well as joint ERS/EBMT Task force guidelines on pulmonary GVHD which are both in the process of publications.

Several other important **studies** were also finalised in the form of publications, including the first real-life experience with cytopenias and organ complications after CAR-T therapies as well as the first AI study conducted in the TCWP on the mortality and NRM after allogeneic HSCT.

Furthermore, the TCWP followed the same successful format of the previous year and conducted a successful **educational meeting** in September in Copenhagen in a format of patient case discussion and sharing practical skills. Patient advocates, nurses and physicians all participated, significantly improving the audience engagement in the activities and resulting in a very positive feedback.

Finally, significant work was also done in the **harmonisation of definitions** for the new EBMT Registry to improve the quality and speed of TCWP studies in the future.

Principal research studies

[Daratumumab for PRCA after alloSCT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Complications: non-infectious](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[Nico Gagelmann](#)

[Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell transplantation](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

Jan Brijs

Outcomes of Allogeneic Hematopoietic Cell Transplantation from $\leq 8/10$ -HLA matched unrelated donor

Study type

Retrospective Studies

Diseases

All diseases

Group

Transplant Complications Working Party (TCWP)

Type of treatment

Allogeneic

Principal investigator

Ivan Moiseev

Outcomes and risk factors for survival of lung transplantation after allogeneic HSCT

Study type

Retrospective Studies

Diseases

-

Group

Transplant Complications Working Party (TCWP)

Type of treatment

Allogeneic

Principal investigator

Juan Montoro Gomez; Saskia Bos

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Study type

Retrospective Studies

Diseases

All diseases

Group

Transplant Complications Working Party (TCWP)

Type of treatment

Allogeneic

Principal investigator

Olaf Penack

Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation

Outcomes

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Mustafa Güven](#)

Key publications

[2023](#)

[Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Infectious Diseases Working Party \(IDWP\)](#)

[Transplant Complications Working Party \(TCWP\)](#)

[1st listed author](#)

[Olaf Penack](#)

[Journal](#)

[J Immunother Cancer.](#)

[2023](#)

[Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Olaf Penack](#)

[Journal](#)

[Front Immunol.](#)

[2023](#)

[ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party](#)

Group

Transplant Complications Working Party (TCWP)

1st listed author

Olaf Penack

Journal

Front Immunol.

2023

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Group

Transplant Complications Working Party (TCWP)

1st listed author

Lars Kligen Gjørde

Journal

Bone Marrow Transplant.

2023

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

Group

Transplant Complications Working Party (TCWP)

1st listed author

A Mussetti

Journal

Bone Marrow Transplant.

2023

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study

Group

Transplant Complications Working Party (TCWP)

1st listed author

Tapani Ruutu

Journal

Bone Marrow Transplant.

2023

Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications

[Working Party of the EBMT](#)

[Group](#)


[Transplant Complications Working Party \(TCWP\)](#)

[1st listed author](#)

[Lars Klingen Gærde](#)

[Journal](#)

[Bone Marrow Transplant.](#)



2021 2022 2023

Oral presentations 2 6 **1**

Poster presentations 2 5 **9**

Educational events 1 1 **1**

Major educational events



[Event](#)

49th Annual Meeting of the EBMT



[Event](#)

TCWP Educational Meeting 2023 on How to survive stem cell transplantation and CAR T-cell therapy - guide for physicians and nurses

Sep 14, 2023 - Sep 16, 2023 / Copenhagen, Denmark

Discover more

VISIT THE TCWP WEBPAGE